Neumora Therapeutics (NMRA) Competitors $1.27 -0.02 (-1.55%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$1.25 -0.02 (-1.57%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. TYRA, TSHA, OPT, BCYC, KURA, SEPN, ABVX, MAZE, PRME, and VALNShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Tyra Biosciences (TYRA), Taysha Gene Therapies (TSHA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Septerna (SEPN), Abivax (ABVX), Maze Therapeutics (MAZE), Prime Medicine (PRME), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Tyra Biosciences Taysha Gene Therapies Opthea Bicycle Therapeutics Kura Oncology Septerna Abivax Maze Therapeutics Prime Medicine Valneva Tyra Biosciences (NASDAQ:TYRA) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment. Do insiders and institutionals hold more shares of TYRA or NMRA? 84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 15.2% of Tyra Biosciences shares are held by company insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer TYRA or NMRA? Tyra Biosciences presently has a consensus target price of $30.83, suggesting a potential upside of 182.62%. Neumora Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 490.55%. Given Neumora Therapeutics' higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Tyra Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tyra Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is TYRA or NMRA more profitable? Tyra Biosciences' return on equity of -26.90% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tyra BiosciencesN/A -26.90% -25.54% Neumora Therapeutics N/A -84.79%-77.57% Does the media prefer TYRA or NMRA? In the previous week, Tyra Biosciences and Tyra Biosciences both had 3 articles in the media. Neumora Therapeutics' average media sentiment score of 1.00 beat Tyra Biosciences' score of 0.63 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tyra Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TYRA or NMRA? Tyra Biosciences has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the S&P 500. Which has stronger earnings and valuation, TYRA or NMRA? Tyra Biosciences is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTyra BiosciencesN/AN/A-$86.48M-$1.63-6.69Neumora TherapeuticsN/AN/A-$243.79M-$1.61-0.79 SummaryTyra Biosciences and Neumora Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$205.42M$2.95B$5.54B$9.14BDividend YieldN/A2.43%5.01%4.00%P/E Ratio-0.7921.1628.6919.45Price / SalesN/A184.72372.4779.78Price / CashN/A41.0524.7227.47Price / Book0.717.758.215.58Net Income-$243.79M-$55.05M$3.19B$252.81M7 Day Performance40.85%9.69%3.60%2.11%1 Month Performance50.38%13.80%9.61%11.87%1 Year Performance-89.06%3.55%30.04%16.61% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.704 of 5 stars$1.27-1.6%$7.50+490.6%-88.5%$205.42MN/A-0.79108Positive NewsGap UpTYRATyra Biosciences3.1247 of 5 stars$9.61-3.9%$30.83+220.8%-44.9%$530.90MN/A0.0020TSHATaysha Gene Therapies4.0478 of 5 stars$2.34-4.5%$8.20+250.4%+11.4%$525.92M$8.33M0.00180News CoverageOPTOpthea0.3949 of 5 stars$3.41+7.2%$1.33-60.9%+69.7%$524.84M$120K0.008Gap UpBCYCBicycle Therapeutics3.1927 of 5 stars$7.17-3.5%$25.00+248.7%-64.3%$514.56M$35.28M0.00240KURAKura Oncology4.5224 of 5 stars$5.68-3.1%$24.50+331.3%-71.6%$507.33M$53.88M0.00130Positive NewsSEPNSepterna1.5521 of 5 stars$10.85-4.6%$26.75+146.5%N/A$506.63M$1.08M0.00N/AABVXAbivax2.0976 of 5 stars$7.95-0.1%$31.00+289.9%-35.2%$505.10MN/A0.0061News CoverageHigh Trading VolumeMAZEMaze TherapeuticsN/A$12.12+5.4%$25.67+111.8%N/A$503.67M$167.50M0.00121PRMEPrime Medicine3.7869 of 5 stars$3.80+22.2%$10.08+165.4%-15.9%$498.92M$3.85M-1.85234High Trading VolumeVALNValneva1.8126 of 5 stars$5.75-1.0%$15.50+169.6%-16.7%$494.40M$183.52M0.00700Gap Down Related Companies and Tools Related Companies Tyra Biosciences Competitors Taysha Gene Therapies Competitors Opthea Competitors Bicycle Therapeutics Competitors Kura Oncology Competitors Septerna Competitors Abivax Competitors Maze Therapeutics Competitors Prime Medicine Competitors Valneva Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
